What AstraZeneca's woes say about ESG investing
Global multi-national businesses with billions of pounds in revenue and profit aren't obvious candidates for sympathy but it's hard not to feel a bit sorry for AstraZeneca (AZN) after its experience over the last six months.In...
08 April 2021
